Sarepta Issues Statement on ELEVIDYS Patient Death
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the...
Category : Healthcare Quality, Patient Safety & Policy
BeOne’s TEVIMBRA Gets CHMP Nod for NSCLC Treatment
Recommendation based on Phase 3 RATIONALE-315 study, in which TEVIMBRA demonstrated clinically meaningful and statistically significant improvement in event-free survival and major pathological response If...
Malaysia Launches MYMT 2026, Its 1st Medical Tourism Year
The Malaysia Healthcare Travel Council (MHTC) launched Malaysia Year of Medical Tourism (MYMT) 2026 today at the Malaysia International Trade and Exhibition Centre (MITEC). The Honourable Datuk...
IDEAYA & Hengrui to Present IDE849 at IASLC 2025 Lung Cancer Conf
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), a global pharmaceutical company focused on scientific and...
Humana Speeds Up Prior Authorization Removal for Faster Care
New effort will expedite approvals, promote access to care, reduce administrative burdens, and enhance the patient experience Humana Inc., a leading health and well-being company,...
MVP Health & Renalytix Partner to Expand Kidney Disease Testing
New partnership expands access to prognostic testing for people with diabetic kidney disease, helping improve lives and reduce health disparities. Renalytix Plc, a precision medicine...
Cybin Gets MHRA OK to Start EMBRACE Study of CYB003 for MDD
– EMBRACE, the second Phase 3 study within the PARADIGM program, expects to enroll 330 participants at approximately 60 clinical sites across the United States, Europe...
AdventHealth, Anthem Sign Multi-Year Deal to Expand GA Access
AdventHealth and Anthem Blue Cross Blue Shield of Georgia (Anthem) are pleased to announce a new multi-year contractual agreement that ensures continued access to high-quality,...
Alzheon to Share ALZ-801 Data at Alzheimer’s Conference July 30′
Valiltramiprosate Evaluated in APOLLOE4 Trial, First Interventional Phase 3 Alzheimer’s Trial Focused on High-Risk APOE4/4 Homozygotes Anti-Amyloid Oligomer Action Underpins Valiltramiprosate’s Potential Benefit in Alzheimer’s...
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces a favorable outcome in opposition proceedings before the...
Bio-Techne’s Simple Western Used in FDA Approval of ZEVASKYN™ Therapy
Bio-Techne Corporation (NASDAQ: TECH) today announced that its Simple Western™ Technology played a key role in supporting the FDA approval of ZEVASKYN™ (prademagene zamikeracel), the first...
Genomenon & UCB Partner to Boost TK2 Deficiency Awareness and Diagnosis
Genomenon’s Curation and Distribution of Variant Data to Global Clinical Communities Reduces Barriers to Genetic Diagnosis Genomenon, a leader in genomic intelligence, today announced a...
International SOS Calls for Innovation in Crisis Management
New Comprehensive Global Crisis Management White Paper Leads the Way to Transform Crises into Catalysts for Resilience and Innovation International SOS, the leading global security and...
Manitoba Bioscience Group Applauds Government Support for Research
Bioscience Association Manitoba (BAM) welcomes the Manitoba government’s latest announcement to launch a Clinical Trials Office, and the implementation of the Research Manitoba led project,...
Dizal’s ZEGFROVY® Gets FDA Accelerated Approval for NSCLC Treatment
Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the U.S. Food and...